Corporate | 21 May 2015 10:19
|
MeVis Medical Solutions AG / Key word(s): Quarter Results/Interim Report
Very positive sales by strong US Dollar, declining results
Bremen, May 21, 2015 – MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, today announced its results for the first quarter of 2015. Sales in the first quarter of 2015 came to EUR 3,408 k, 21 % higher than in the first quarter of 2014 (EUR 2,828 k). Revenues generated from licensing business increased by 17 % to TEUR 1,561, revenues from maintenance business increased by 9 % and accounted with TEUR 1,493 for 44 % of total sales. Sales in the Digital Mammography segment grew by 22 % to EUR 2,721 k (prev. year: EUR 2,227 k) and sales in the Other Diagnostics segment grew by 14 % to EUR 687 k (prev. year: EUR 601 k). Operating expenses increased slightly in the first quarter of 2014. Staff costs increased by only 1 % to EUR 1,837 k (prev. year: EUR 1,812 k). Other operating expenses rose by 34 % to EUR 549 k (prev. year: EUR 411 k) driven by legal and consulting cost. The capitalization of development expenses was ceased in the fourth quarter of 2014 (Q1 2014: EUR 428 k). Due to increased sales and despite higher costs and the cessation of the capitalization of development expenses, we see a slight increase of the EBITDA (earnings before interest, taxes, depreciation and amortization) by 1 %, from EUR 1,100 k to EUR 1,107 k. After depreciation and amortization of EUR 565 k (up 39 % year on year), EBIT (earnings before interest and taxes) declined considerably by 22 % to EUR 542 k (prev. year: EUR 694 k) corresponding to an EBIT margin of 16 % (prev. year: 25 %). The net financial result improved by EUR 59 k to EUR 138 k year on year. Mainly the development of the US$ exchange rate, the continuous improvement of the MeVis BreastCare, and the interest result have contributed to this. Income tax expenses decreased by EUR 46 k to EUR 42 k. Net profit fell by EUR 47 k to EUR 683 k, which is equivalent to earnings per share of EUR 0,37 (prev. year: 0,40). Cash and cash equivalents increased by EUR 1.453 k to EUR 18.964 k as of March 31, 2015 compared to the end of 2014. The Company’s financial reports can be downloaded from the following website: http://www.mevis.de/en/investor-relations/financial-reports/
2015-05-21 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
| Language: | English | |
| Company: | MeVis Medical Solutions AG | |
| Caroline-Herschel-Str. 1 | ||
| 28359 Bremen | ||
| Germany | ||
| Phone: | +49 421 224 95 0 | |
| Fax: | +49 421 224 95 999 | |
| E-mail: | ir@mevis.de | |
| Internet: | http://www.mevis.de | |
| ISIN: | DE000A0LBFE4 | |
| WKN: | A0LBFE | |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart | |
| End of News | DGAP News-Service |
|
|
| 360419 2015-05-21 |